

Celgene Acquires Abraxis BioScience and Leading Anti-Cancer Drug Abraxane

Melbourne 20 October 2010: Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Abraxis BioScience, Inc. The transaction adds Abraxane® (nanoparticle albumin-bound paclitaxel) to the company's existing portfolio of leading cancer products and offers another significant scientific platform that may drive future development.

PBS Change for Leading Breast Cancer Drug ABRAXANE®

Melbourne, 7 June 2010: Melbourne pharmaceutical company Specialised Therapeutics Australia (STA) wishes to announce a change in the Pharmaceutical Benefits Scheme (PBS) listing for its lead product ABRAXANE® (nanoparticle albumin-bound paclitaxel).

Study Shows Leading Breast Cancer Drug ABRAXANE® Increases Survival Time for

Advanced Pancreatic Cancer

MELBOURNE, May, 2010: An international study of world-leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) has shown promising results for patients with advanced pancreatic cancer when used in combination with Gemcitabine.

ABRAXANE® Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer

LOS ANGELES and MELBOURNE - March 18, 2010: An international lung cancer trial has shown positive results in those patients treated with the leading breast cancer drug ABRAXANE in combination with carboplatin.

ABRAXANE® Granted Orphan Drug Status for Pancreatic Cancer by Therapeutic Goods Administration

Melbourne, February 2010: A leading Australian breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been granted orphan

drug status by the Therapeutic Goods Administration (TGA) for pancreatic cancer.